Clinical reference Biomarker Directory
Back to directory

Gamma-Enolase

Established

NSE is a tumor marker for neuroendocrine-origin cancers, used for diagnosis and treatment monitoring.

Also known as NSE neuron-specific enolase
In plain language

This enzyme, found in nerve and hormone-producing cells, becomes a tumor marker for certain cancers like small cell lung cancer and neuroblastoma, and can serve as a backup marker for neuroendocrine tumors when the usual test (chromogranin A) gives a confusing result.

Biomarker & context

Gamma-enolase, also called neuron-specific enolase (NSE), is a glycolytic enzyme found in neurons and neuroendocrine cells, used as a tumor marker for cancers of neuroendocrine origin.

What it indicates

Elevated NSE supports diagnosis and monitoring of small cell lung cancer and neuroblastoma, and is increasingly explored as a supplementary marker for neuroendocrine tumors when chromogranin A is unreliable, such as in patients on proton pump inhibitors.

Diagnosis & clinical testing

Measured via serum immunoassay; often ordered alongside pro-gastrin-releasing peptide (ProGRP) in suspected small cell lung cancer, and alongside chromogranin A in broader neuroendocrine tumor workups when CgA results are ambiguous.

Guiding treatment

Serial NSE tracks treatment response in small cell lung cancer and neuroblastoma; combining NSE with sIL-2R and ACE has also been studied to help distinguish sarcoidosis from malignancy in ambiguous cases.

Clinical significance

Useful supplementary marker when chromogranin A results are confounded by medication interference.

References
  1. PMC. (2022). Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis.